KLRS 8-K 2026-11-10
Kalaris Therapeutics, Inc. (KLRS) 8-K dated 2026-11-10 — accession 0001193125-26-454454.
Kalaris Therapeutics, Inc. (KLRS) is a biotechnology company listed on US.
KLRS: Kalaris Reports Third Quarter 2026 Financial Results and Provides Busin…
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Income-statement cache for KLRS is thin on this filing URL. We will not invent exhibit numbers.
Not investment advice. The KLRS SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects that its cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund its opera
Why it matters
- expects that its cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund its opera
- Kalaris made meaningful progress in the third quarter,…